Tag Archives: PDT

Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration (AMD) Age-related Macular Degeneration (AMD) is a disease causing choroidal neovascularization (CNV) and consequent irreversible damage in the macula. AMD is classified into dry (atrophic) and wet (exudative) forms, with the latter causing faster vision loss and being the leading cause of blindness in people over 65. Introduction to AMD Age-related Macular Degeneration (AMD) is one of the leading causes for  visual impairment. AMD is charactirized by development of Choroidal neovascularization (CNV) and consequent irreversible damage in the macula. CNV means abnormal Continue reading →

Photodynamic Therapy for Cancer Treatment – Review Article by Nature

 Modulight Corp., a leader in innovative laser solutions, is proud to announce a significant contribution to the field of cancer treatment through the publication of a comprehensive review on Photodynamic Therapy (PDT) in Nature Reviews Bioengineering. This review article, co-authored by Modulight’s CTO Dr. Petteri Uusimaa, alongside several other leading experts, highlights the transformative potential of PDT in cancer treatment, priming, and imaging. The review article, titled “Engineering Photodynamics for Treatment, Priming, and Imaging”, explores the advanced applications of PDT, a photochemistry-based treatment approach that Continue reading →

Engineering Photodynamics for Treatment, Priming and Imaging

 Published in: Nature Reviews Bioengineering Authors: Girgis Obaid, University of Texas at Dallas Jonathan P. Celli, University of Massachusetts Boston Mans Broekgaarden, Grenoble Alpes University Anne-Laure Bulin, Grenoble Alpes University Petteri Uusimaa, Modulight Corporation Brian Pogue, University of Wisconsin School of Medicine Tayyaba Hasan, Harvard Medical School Huang-Chiao Huang, University of Maryland   The review article explores the advanced applications of PDT, a photochemistry-based treatment approach that utilizes light-activated photosensitizers to generate reactive oxygen species for localized cellular cytotoxicity. The paper discusses the underlying mechanisms Continue reading →

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model

Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman  Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman Three forms of localized tumor destruction (radiation therapy, vascular targeted PDT and cryoablation) were compared for their efficacy in evoking local and systemic immune responses. This has potential to improve effectiveness of immunotherapy in non-responding patients (cold tumors) by attracting T cells to the Continue reading →

Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties

Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland  Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland A series of Ru(II) complexes were characterized and assessed for phototherapy effects toward cancer cells. Also activity in hypoxia was evaluated, with some of the compounds retaining partial activity in hypoxia. ML8500 was used for dosimetry studies, assessing impact of irradiance on the phototoxicity of Ru-4T with several different wavelengths. LEDs were used for Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

ML7710 for photoactivated treatment of lung cancer

Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →Published in: Science Advances Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*) (1) Fischell Department of Bioengineering, University of Maryland (2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health (3) Modulight Corp., Finland (4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine (5) Department of Obstetrics, Gynecology and Reproductive Sciences, University Continue reading →

Photodynamic Therapy of an Abdominal Abscess at the Time of Percutaneous Drainage

Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma    Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma   This article presents a successful case study from an ongoing Phase 1 clinical trial where methylene blue together with ML7710 is used to eradicate bacteria and biofilm in the treatment of persistent abscesses. The potential of Photodynamic Therapy (PDT) is explored as an adjunct treatment for recurrent or challenging-to-manage abdominal abscesses during percutaneous drainage procedures. Despite advancements in abscess drainage techniques and antibiotics, some cases exhibit low response rates and recurrences, Continue reading →